A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial

Daisuke Tomizawa, Takako Miyamura, Toshihiko Imamura, Tomoyuki Watanabe, Akiko Moriya Saito, Atsushi Ogawa, Yoshihiro Takahashi, Masahiro Hirayama, Tomohiko Taki, Takao Deguchi, Toshinori Hori, Masashi Sanada, Shigeru Ohmori, Masami Haba, Akihiro Iguchi, Yuki Arakawa, Yuhki Koga, Atsushi Manabe, Keizo Horibe, Eiichi IshiiKatsuyoshi Koh

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)

Abstract

The prognosis for infants with acute lymphoblastic leukemia (ALL), particularly those with KMT2A gene rearrangement (KMT2A-r), is dismal. Continuous efforts have been made in Japan to investigate the role of hematopoietic stem cell transplantation (HSCT) for infants with KMT2A-r ALL, but improvement in outcome was modest. In the Japanese Pediatric Leukemia/Lymphoma Study Group MLL-10 trial, infants with ALL were stratified into 3 risk groups (low risk [LR], intermediate risk [IR], and high risk [HR]) according to KMT2A status, age, and presence of central nervous system leukemia. Children’s Oncology Group AALL0631 modified chemotherapy with the addition of high-dose cytarabine in early intensification was introduced to KMT2A-r patients, and the option of HSCT was restricted to HR patients only. The role of minimal residual disease (MRD) was also evaluated. Ninety eligible infants were stratified into LR (n 5 15), IR (n 5 19), or HR (n 5 56) risk groups. The 3-year event-free survival (EFS) rate for patients with KMT2A-r ALL (IR 1 HR) was 66.2% (standard error [SE], 5.6%), and for those with germline KMT2A (KMT2A-g) ALL (LR), the 3-year EFS rate was 93.3% (SE, 6.4%). The 3-year EFS rate was 94.4% (SE, 5.4%) for IR patients and 56.6% (SE, 6.8%) for HR patients. In multivariable analysis, female sex and MRD ‡0.01% at the end of early consolidation were significant factors for poor prognosis. Risk stratification and introduction of intensive chemotherapy in this study were effective and were able to eliminate HSCT for a subset of infants with KMT2A-r ALL. Early clearance of MRD seems to have translated into favorable outcomes and should be incorporated into risk stratifications in future trials. This trial was registered at the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) as #UMIN000004801.

Original languageEnglish
Pages (from-to)1813-1823
Number of pages11
JournalBlood
Volume136
Issue number16
DOIs
Publication statusPublished - Oct 2020
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint

Dive into the research topics of 'A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial'. Together they form a unique fingerprint.

Cite this